Industry Focus

Healthcare: 3 Beaten-Up Biotechs -- Are They Buys?

10.09.2019 - By The Motley FoolPlay

Download our free app to listen on your phone

Download on the App StoreGet it on Google Play

Here's why post-approval setbacks have caused Puma Biotechnology, Clovis Oncology, and Regenxbio shares to tumble, and if any of these stocks are finally worth buying. Stocks: PBYI, CLVS, RGNX Check out more of our content here: TMF's podcast portal YouTube Twitter Join Our Motley Fool Podcast Facebook Group LinkedIn StockUp, The Motley Fool's weekly email newsletter

More episodes from Industry Focus